ERBB2 and non-small cell lung carcinoma: In a phase II clinical trial for HER-2-overexpressing or HER-2-mutated NSCLC (NCT03505710), the results showed that the ORR of Enhertu ([fam]-trastuzumab deruxtecan, an HER-2 ADC) was 61.9% and the median PFS was 14 months.